Boston Scientific Q3 Earnings: Revenue And EPS Beat, Lifts Annual Forecast On Strong Demand For Heart Devices

On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter revenues of $4.21 billion, beating the consensus estimate of $4.04 billion.

Sales increased 19.4% on a reported basis, compared to the company's guidance range of 13%-15%, and 19.5% on an operational basis, 18.2% on an organic basis, compared to the company's guidance range of 13%-15%.

The company earned an adjusted EPS of $0.63, beating the consensus of $0.59 and the management guidance of $0.57-$0.59.

The company's cardiovascular segment generated sales of $2.73 billion, rising 25% (25.1% operationally and 24.6% organically).

Boston Scientific reported 29.2% growth for cardiology products and 11.8% growth in peripheral interventions.

MedSurg segment revenues increased ...